(Q36577234)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Drug Insight: interferon treatment in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Richard A Rudick

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Neurology

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

34-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

A comprehensive assessment of the cost of multiple sclerosis in the United States.

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

A brief history of the use of interferons as treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10?

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

A magnetization transfer histogram study of normal-appearing brain tissue in MS

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

The placebo effect in neurological disorders.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0088

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16932519%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference